ObjectiveTo establish a mouse model of particulate matter 2.5 （PM_2.5）-induced dry eye and investigate whether Chufeng Yisuntang can ameliorate the PM_2.5-induced ocular surface damage by regulating the reactive oxygen species （ROS）/p38 mitogen-activated protein kinase （p38 MAPK） signaling pathway. MethodsSixty 8-week-old male C57BL/6J mice were used. Ten were randomly selected as the control group. The remaining 50 mice received topical instillation of 1 drop （0.1 mL） of 5 g·L^-1 PM_2.5 suspension in both eyes， four times daily. Successfully modeled mice were randomized into four groups （n=10）： Model， p38 MAPK inhibitor， Chufeng Yisuntang， and combination （Chufeng Yisuntang at 7.3 g·kg^-1 + p38 MAPK inhibitor SB203580 at 5 mg·kg^-1）. Chufeng Yisuntang was administered via gavage， and the inhibitor group via intraperitoneal injection. The control and model groups received equal volumes of distilled water by gavage. All treatments lasted for 4 weeks. General conditions were dynamically observed. Tear secretion， tear film break-up time， and corneal fluorescein staining were assessed. After intervention for 4 weeks， hematoxylin and eosin （HE） staining was used to examine the histopathological changes. Enzyme-linked immunosorbent assay （ELISA） was adopted to measure serum levels of ROS， malondialdehyde （MDA）， superoxide dismutase （SOD） 1， and SOD2. Western blot and Real-time PCR were employed to determine the protein and gene levels， respectively， of p38 MAPK， B-cell lymphoma-2 （Bcl-2）， Bcl-2-associated X protein （Bax）， and cysteinyl aspartate-specific proteinase-3 （Caspase-3） in the corneal tissue. ResultsCompared with the control group， the model group exhibited reduced tear secretion volume and tear film breakup time， along with increased corneal fluorescein staining scores （P<0.01）. Compared with the model group， the Chufeng Yisuntang group， p38 MAPK inhibitor group， and combination group demonstrated increased tear secretion volume and tear film breakup time， along with decreased corneal fluorescein staining scores （P<0.01）. HE staining revealed that compared with the control group， the model group exhibited marked increases in corneal epithelial cell layers and epithelial thickness， along with reduced meibomian gland acini and intensely stained， densely packed nuclei around the acini. Compared with the model group， the Chufeng Yisuntang group， p38 MAPK inhibitor group， and combination group showed intact corneal structure， improved cell morphology， and reduced damage severity. ELISA revealed elevated ROS and MDA levels （P<0.01） and decreased SOD1 and SOD2 levels （P<0.01） in the model group compared with the control group. Compared with the model group， Chufeng Yisuntang， p38 MAPK inhibitor， and the combination lowered ROS and MDA levels （P<0.01）， while raising SOD1 and SOD2 levels （P<0.05， P<0.01）. Western blot revealed that compared with the control group， the model group exhibited increased protein levels of p38 MAPK， Bax， and Caspase-3 （P<0.01） and reduced protein level of Bcl-2 （P<0.01）. Compared with the model group， Chufeng Yisuntang， p38 MAPK inhibitor， and the combination down-regulated the protein levels of p38 MAPK， Bax， and Caspase-3 （P<0.01）， while up-regulating the protein level of Bcl-2 （P<0.01）. Compared with the Chufeng Yisuntang group， the combination group exhibited decreased protein levels of p38 MAPK， Bax， and Caspase-3 （P<0.01） and increased protein level of Bcl-2 （P<0.01）. Real-time PCR revealed that compared with the control group， the model group exhibited upregulated mRNA levels of p38 MAPK， Bax， and Caspase-3 （P<0.01）， and downregulated mRNA level of Bcl-2 （P<0.01）. Compared with the model group， Chufeng Yisuntang， p38 MAPK inhibitor， and the combination down-regulated the mRNA levels of p38 MAPK， Bax， and Caspase-3 （P<0.01）， while up-regulating the mRNA level of Bcl-2 （P<0.05， P<0.01）. Compared with the Chufeng Yisuntang group， the combination group exhibited decreased mRNA levels of p38 MAPK， Bax， and Caspase-3 expression （P<0.05， P<0.01） and increased mRNA level of Bcl-2 （P<0.01）. ConclusionChufeng Yisuntang may partially protect against PM_2.5-induced corneal injury by inhibiting the ROS/p38 MAPK pathway， enhancing antioxidant defense， and reducing epithelial apoptosis.

Objective To analyze the trajectory of cardiovascular health score and its influencing factors in patients with CHD after PCI based on LCGM.Methods A total of 186 CHD patients undergoing PCI in our hospital from June 2021 to June 2023 were enrolled,and all of them re-ceived an assessment for cardiovascular health scores.LCGM analysis was performed on the change in their postoperative cardiovascular health scores.Multivariate logistic regression analysis was applied to identify the factors affecting the trajectory of the change in the scores of the patients.Results The cardiovascular health score was 6.34±1.38,6.76±1.44,7.49±1.85,and 8.06±2.07,respectively on the day of,and at 1,6 and 12 months after surgery.There were signifi-cant differences in the score among different time points(F=37.167,P＜0.01).LCGM model constructed by quadratic estimation showed that the trajectory of the cardiovascular health score in CHD patients after PCI could be divided into three types:growth type(98 cases,52.69％),sta-ble type(67 cases,36.02％)and volatile type(21 cases,11.29％).Statistical difference was ob-served in the score among the post-PCI CHD patients with different education level,per capita monthly family income,duration of coronary artery disease,and number of comorbid chronic dis-eases(P＜0.05,P＜0.01).The education level,per capita monthly family income,duration of cor-onary heart disease,and number of comorbid chronic diseases were all influencing factors for the trajectory of cardiovascular health score in the CHD patients after PCI(P＜0.01).Conclusion There are three types of trajectory in cardiovascular health score of CHD patients after PCI.Edu-cation level,family per capita monthly income,duration of coronary heart disease and number of chronic diseases are independent factors affecting the score of the patients.

Objective To analyze the trajectory of cardiovascular health score and its influencing factors in patients with CHD after PCI based on LCGM.Methods A total of 186 CHD patients undergoing PCI in our hospital from June 2021 to June 2023 were enrolled,and all of them re-ceived an assessment for cardiovascular health scores.LCGM analysis was performed on the change in their postoperative cardiovascular health scores.Multivariate logistic regression analysis was applied to identify the factors affecting the trajectory of the change in the scores of the patients.Results The cardiovascular health score was 6.34±1.38,6.76±1.44,7.49±1.85,and 8.06±2.07,respectively on the day of,and at 1,6 and 12 months after surgery.There were signifi-cant differences in the score among different time points(F=37.167,P＜0.01).LCGM model constructed by quadratic estimation showed that the trajectory of the cardiovascular health score in CHD patients after PCI could be divided into three types:growth type(98 cases,52.69％),sta-ble type(67 cases,36.02％)and volatile type(21 cases,11.29％).Statistical difference was ob-served in the score among the post-PCI CHD patients with different education level,per capita monthly family income,duration of coronary artery disease,and number of comorbid chronic dis-eases(P＜0.05,P＜0.01).The education level,per capita monthly family income,duration of cor-onary heart disease,and number of comorbid chronic diseases were all influencing factors for the trajectory of cardiovascular health score in the CHD patients after PCI(P＜0.01).Conclusion There are three types of trajectory in cardiovascular health score of CHD patients after PCI.Edu-cation level,family per capita monthly income,duration of coronary heart disease and number of chronic diseases are independent factors affecting the score of the patients.

By exploring the theory of “the liver is the basis of resistance to fatigue”， it is believed that liver with its physiological function of storing blood and governing the free flow of qi plays an important role in the body's tole-rance to physical fatigue and mental fatigue， and it is also related to the physiological activities of eyes and tendons. The formation of asthenopia is related to the dysfunction of liver， spleen and kidney. The liver plays a key role in the occurrence and development of asthenopia. The deficiency of liver blood and liver dysfunction will cause the abnormal circulation of qi and blood， which leads to the loss of malnutrition of eyes and affects the normal physiological function of eyes. During treatment， we pay attention to nourishing the blood and soothing the liver to nourish the spirit， regulating and tonifying liver qi to stimulate the liver yang， strengthening the spleen and soothing liver to replenish qi and promoting yang， nourishing the liver and kidney to harmonize yin and yang， which are meant to restore the physiological characteristics of liver being yin in form but yang in function， so as to cure asthenopia.

Objective To investigate the clinicopathological features and key points of diagnosis and treatment of malignant perivascular epithelioid cell tumor(PEComa)to increase awareness of the disease.Methods The clinicopathological data of 2 patients with malignant PEComa treated in our hospital were retrospectively analyzed,and relevant literatures were reviewed.Results Both patients were male,aged 53 and 16 years,respectively.The sites of occurrence were in the retroperitoneum and pelvis,respectively.Both tumors were resected surgically,and the diagnosis was confirmed with postoperative pathology.Under the microscope,the tumor tissue of one patient was mainly composed of smooth muscle-like cells,and that of the other patient was composed of epithelioid cells,both showing pathological mitotic images and expressing HMB45,Melan-A,SMA and CD34,no tumor recurrence or metastasis was observed during the follow-up.The literatures collected involved 15 patients with retroperitoneal or pelvic PEComa,including 3 males and 12 females,of which 9 were malignant.The clinical manifestations were abdominal pain,bloating,or lower back pain.Some cases were detected during physical examinations.Conclusion Malignant PEComa is difficult to be diagnosed before surgery and easy to be misdiagnosed.The confirmed diagnosis depends on the postoperative pathological results.The preferred treatment is complete resection of tumor.Long-term follow-up is needed.

Complex brain diseases seriously endanger human health, and early diagnostic biomarkers and effective treatments are currently lacking. Due to ethical constraints on human research, establishing monkey models is crucial to address these issues. With the rapid development of technology, transgenic monkey models of a range of brain diseases, especially autism spectrum disorder (ASD), have been successfully established. However, to establish practical and effective brain disease models and subsequently apply them to disease mechanism and treatment studies, there is still a lack of a standard tool, i.e., a system for collecting and analyzing the daily behaviors of brain disease model monkeys. Therefore, with the goal of undertaking a comprehensive and quantitative study of behavioral phenotypes, we established a standard daily behavior collection and analysis system, including behavioral data collection protocols and a monkey daily behavior ethogram (MDBE) for rhesus and cynomolgus monkeys, which are the most commonly used non-human primates in model construction. Then, we used ASD as an application example after referring to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), which is widely used in clinical disease diagnosis to obtain ASD core clinical symptoms. We then established a sub-ethogram (ASD monkey core behavior ethogram (MCBE-ASD)) specifically for quantitative assessment of the core clinical symptoms of an ASD monkey model based on MDBE. Subsequently, we demonstrated the high reproducibility of the system.
Animals ; Autism Spectrum Disorder ; Macaca mulatta ; Disease Models, Animal ; Behavior, Animal ; Macaca fascicularis ; Male ; Humans

Objective:To systematically evaluate whether the early use of bracing after posterior lumbar fusion has advantages in terms of the improvement of clinical outcomes such as pain, functional disability, fusion rate, and complication rate in patients with lumbar degenerative diseases.Methods:All randomized controlled trials of bracing performed after posterior lumbar fusion in patients with lumbar degenerative diseases were searched in Pubmed, Web of Science, Embase, China national knowledge infrastructure (CNKI) and Wanfang database from January 1990 to May 2022. The data extracted were authors, year of publication, nationality, subject characteristics, sample size, surgical protocol, type and time of bracing, follow-up duration, preoperative and postoperative Oswestry disability index (ODI) and visual analogue scale (VAS), postoperative fusion rate and complication rate. The Cochrane Risk of Bias tool was used to evaluate the risk of bias. The use of fix- or random-effect models was depended on the magnitude of heterogeneity. Data analysis was performed using Stata 17.0 statistical software for meta analysis.Results:A total of five randomized controlled trials were included, all in English, with a total of 362 patients (male 144, female 218). The results of meta-analysis showed that there was no statistically significant difference in the improvement of ODI scores [ MD=1.25, 95% CI(-2.39, 4.88), P=0.501]and VAS scores[ MD=0.21, 95% CI(-0.22, 0.63), P=0.340]between the brace group and the control group after operation. In terms of fusion rate, there was no significant difference between the brace group and the control group[ OR=0.59, 95% CI(0.25, 1.38), P=0.224]. In addition, there was also no significant difference in the incidence of postoperative complications between two groups[ OR=1.12, 95% CI(0.58, 2.15), P=0.735]. Conclusion:The early use of bracing after lumbar fusion has no significant advantages in improving symptoms and functional recovery, fusion rate and surgical complications. The necessity of postoperative bracing after posterior lumbar fusion requires further high-quality research to prove.

Objective: To probe into the correlation between chronic liver disease and intestinal barrier function. Methods: 1 491 cases of hospitalized patients were enrolled, of which 741 cases were of chronic liver diseases, including 397 cases of fatty liver diseases, 230 cases of chronic hepatitis, 114 cases of liver cirrhosis, and 750 cases of non-hepatic diseases. All admitted patients’ intestinal barrier function like diamine oxidase (DAO), D-lactate, lipopolysaccharide, and biochemical indicators of liver functions were tested. According to different data, statistical analysis was done using t-test, ANOVA, Dunnett’s test, χ ² test of fourfold table, Pearson’s correlation, and binary logistic regression. Results: The intestinal barrier dysfunction was more likely to occur in the chronic liver disease group than that of non-hepatic disease group [54.15% (379/741) vs. 18.53% (139/750), χ ² = 193.58, P < 0.001]. The correlation analysis between biochemical indicators of liver function and intestinal barrier function in chronic liver disease group showed that alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), and total bilirubin levels were more susceptible to intestinal barrier dysfunction than those with normal indexes (P < 0.05 ). GGT had stimulated DAO (P < 0.05, OR > 1), D-lactate (P < 0.05, OR > 1), lipopolysaccharide (P < 0.05, OR > 1), ALT and AST. Conclusion Chronic liver disease increases with damage to intestinal barrier function.

Objective 5BTo study the effects of desloratadine on the level of IL-4 and IL-13 in bronchoalveolar lavage fluid of allergic asthmatic rat model.Methods The allergic asthmatic rat model was induced by ovalbumin.Then the effects of desloratadine on the latent period of asth-ma,the level of IL-4 and IL-13 in bronchoalveolar lavage fluid were observed.Results Deslorata-dine could extend the latent period of asthma,and decrease the level of IL-4 and IL-13 in bron-choalveolar lavage fluid.Conclusion Desloratadine could delay the onset of asthma by decreasing the level of IL-4 and IL-13.So it provides basis for the clinical use in treating asthma.

Objective 5BTo study the effects of desloratadine on the level of IL-4 and IL-13 in bronchoalveolar lavage fluid of allergic asthmatic rat model.Methods The allergic asthmatic rat model was induced by ovalbumin.Then the effects of desloratadine on the latent period of asth-ma,the level of IL-4 and IL-13 in bronchoalveolar lavage fluid were observed.Results Deslorata-dine could extend the latent period of asthma,and decrease the level of IL-4 and IL-13 in bron-choalveolar lavage fluid.Conclusion Desloratadine could delay the onset of asthma by decreasing the level of IL-4 and IL-13.So it provides basis for the clinical use in treating asthma.